To evaluate the effect of statin use on recurrence and mortality in hormone receptor-positive (HR+) breast cancer patients through a comprehensive meta-analysis, highlighting its potential clinical significance.
Key Findings:
Statin use was associated with a 23% reduction in recurrence risk (HR = 0.77; 95% CI: 0.61–0.98, P = 0.03), suggesting a significant clinical benefit.
Statin use significantly decreased mortality (HR = 0.77; 95% CI: 0.73–0.81, P < 0.001), indicating a potential role in improving survival outcomes.
Sensitivity analyses confirmed the robustness of the findings, reinforcing the reliability of the results.
Interpretation:
Statin therapy may confer a protective effect against recurrence and mortality in HR+ breast cancer patients, suggesting a need for integration into treatment protocols.
Limitations:
Clinical and epidemiological evidence regarding the prognostic impact of statins in HR+ breast cancer remains inconsistent, which may affect the generalizability of the findings.
The study included only observational studies, which may introduce bias and limit causal inferences.
Conclusion:
The findings suggest that statins could serve as an effective adjunctive therapy in HR+ breast cancer, necessitating future large-scale, prospective trials focusing on specific patient populations and treatment regimens.
